Literature DB >> 15201375

Real time PCR quantification of frataxin mRNA in the peripheral blood leucocytes of Friedreich ataxia patients and carriers.

L Pianese1, M Turano, M S Lo Casale, I De Biase, M Giacchetti, A Monticelli, C Criscuolo, A Filla, S Cocozza.   

Abstract

The most common causative mutation of Friedreich ataxia (FRDA) is the unstable hyperexpansion of an intronic GAA triplet repeat that impairs frataxin transcription. Using real time quantitative PCR, we showed that FRDA patients had residual levels of frataxin mRNA ranging between 13% and 30% and that FRDA carriers had about 40% of that of controls. Asymptomatic carriers also showed reduced frataxin mRNA levels. We found an inverse correlation between the number of GAA repeats and frataxin mRNA levels. Real-time quantitative PCR may represent an alternative assay for FRDA molecular diagnosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15201375      PMCID: PMC1739119          DOI: 10.1136/jnnp.2003.028605

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  46 in total

1.  Variations of frataxin protein levels in normal individuals.

Authors:  Therese Boehm; Barbara Scheiber-Mojdehkar; Britta Kluge; Hans Goldenberg; Franco Laccone; Brigitte Sturm
Journal:  Neurol Sci       Date:  2010-05-27       Impact factor: 3.307

Review 2.  Milestones in Friedreich ataxia: more than a century and still learning.

Authors:  Agessandro Abrahão; José Luiz Pedroso; Pedro Braga-Neto; Edson Bor-Seng-Shu; Patricia de Carvalho Aguiar; Orlando Graziani Povoas Barsottini
Journal:  Neurogenetics       Date:  2015-02-08       Impact factor: 2.660

3.  Gene Expression Profile in Peripheral Blood Cells of Friedreich Ataxia Patients.

Authors:  Agessandro Abrahao; Jose Luiz Pedroso; Patricia Maria de Carvalho Aguiar; Orlando Graziani Povoas Barsottini
Journal:  Cerebellum       Date:  2016-06       Impact factor: 3.847

Review 4.  Use of peripheral blood transcriptome biomarkers for epilepsy prediction.

Authors:  Stanislav L Karsten; Lili C Kudo; Anatol J Bragin
Journal:  Neurosci Lett       Date:  2011-03-17       Impact factor: 3.046

5.  Human mesenchymal stem cells increase anti-oxidant defences in cells derived from patients with Friedreich's ataxia.

Authors:  Rimi Dey; Kevin Kemp; Elizabeth Gray; Claire Rice; Neil Scolding; Alastair Wilkins
Journal:  Cerebellum       Date:  2012-12       Impact factor: 3.847

6.  Epigenetic promoter silencing in Friedreich ataxia is dependent on repeat length.

Authors:  Yogesh K Chutake; Christina Lam; Whitney N Costello; Michael Anderson; Sanjay I Bidichandani
Journal:  Ann Neurol       Date:  2014-08-30       Impact factor: 10.422

Review 7.  Small molecules affecting transcription in Friedreich ataxia.

Authors:  Joel M Gottesfeld
Journal:  Pharmacol Ther       Date:  2007-08-09       Impact factor: 12.310

8.  Prospects for the use of artificial chromosomes and minichromosome-like episomes in gene therapy.

Authors:  Sara Pérez-Luz; Javier Díaz-Nido
Journal:  J Biomed Biotechnol       Date:  2010-08-24

9.  Epigenetic silencing in Friedreich ataxia is associated with depletion of CTCF (CCCTC-binding factor) and antisense transcription.

Authors:  Irene De Biase; Yogesh K Chutake; Paul M Rindler; Sanjay I Bidichandani
Journal:  PLoS One       Date:  2009-11-19       Impact factor: 3.240

10.  Altered gene expression and DNA damage in peripheral blood cells from Friedreich's ataxia patients: cellular model of pathology.

Authors:  Astrid C Haugen; Nicholas A Di Prospero; Joel S Parker; Rick D Fannin; Jeff Chou; Joel N Meyer; Christopher Halweg; Jennifer B Collins; Alexandra Durr; Kenneth Fischbeck; Bennett Van Houten
Journal:  PLoS Genet       Date:  2010-01-15       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.